Will the Use of Biomarkers Improve Bladder Cancer Radiotherapy Delivery?

Area of Science:

• Oncology
• Molecular Biology
• Radiotherapy

Background:

• Cancer biology and molecular techniques have improved understanding of cancer development.
• Imaging advances enhance cancer staging, radiotherapy planning, and follow-up.
• Biomarkers are crucial for guiding personalized cancer therapy.

Purpose of the Study:

• To review existing and ongoing research on biomarkers for bladder cancer radiotherapy within trimodality therapy.
• To identify molecular and imaging biomarkers that can personalize treatment selection, radiation delivery, and surveillance.

Main Methods:

• Literature review of current research on bladder cancer biomarkers.
• Analysis of ongoing investigations into predictive and prognostic molecular and imaging markers.

Main Results:

• Significant research is underway to identify biomarkers for bladder cancer.
• A current paucity of biomarkers exists to guide radiotherapy in trimodality treatment.
• Potential biomarkers may guide radiotherapy utilization, radiosensitizer choice, radiation dose/target, and recurrence surveillance.

Conclusions:

• Biomarkers are essential for advancing personalized bladder cancer treatment, particularly in trimodality therapy.
• Further research into molecular and imaging biomarkers is needed to optimize radiotherapy selection and delivery.
• Future biomarker discovery holds promise for improving outcomes and guiding surveillance for bladder cancer patients.